Protox Therapeutics Incorporated (“Protox”) today announced that it has entered into a manufacturing agreement with the Waisman Clinical BioManufacturing Facility (WCBF) at the University of Wisconsin-Madison to manufacture clinical batches of PSA-PA1, its lead product in development for the treatment of localized prostate cancer.
Waisman Biomanufacturing
Expanded Waisman Center Facilities Support Vital Programs
The University of Wisconsin-Madison’s Waisman Center will celebrate the completion of a $25 million expansion project with dedication ceremonies scheduled for Tuesday, September 4. The new facilities will support the center’s pioneering research, services, and education in human development, developmental disabilities, and neurodegenerative diseases.